Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TXG Stock Forecast 2025-2026
$10.87
Current Price
$1.30B
Market Cap
Buy 7
Hold 9
Sell 0
Wall St Analyst Ratings
Distance to TXG Price Targets
+65.6%
To High Target of $18.00
+10.4%
To Median Target of $12.00
-17.2%
To Low Target of $9.00
TXG Price Momentum
+2.7%
1 Week Change
+21.7%
1 Month Change
-45.0%
1 Year Change
-24.3%
Year-to-Date Change
-56.1%
From 52W High of $24.76
+60.3%
From 52W Low of $6.78
📊 TOP ANALYST CALLS
Did TXG Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if 10X Genomics is one of their latest high-conviction picks.
Latest TXG Stock Price Targets & Analyst Predictions
Based on our analysis of 19 Wall Street analysts, TXG has a neutral consensus with a median price target of $12.00 (ranging from $9.00 to $18.00). The overall analyst rating is Buy (7.5/10). Currently trading at $10.87, the median forecast implies a 10.4% upside. This outlook is supported by 7 Buy, 9 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Tejas Savant at Morgan Stanley, projecting a 65.6% upside. Conversely, the most conservative target is provided by Rachel Vatnsdal at JP Morgan, suggesting a 17.2% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TXG Analyst Ratings
7
Buy
9
Hold
0
Sell
TXG Price Target Range
Low
$9.00
Average
$12.00
High
$18.00
Current: $10.87
Latest TXG Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TXG.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 19, 2025 | Morgan Stanley | Tejas Savant | Overweight | Maintains | $18.00 |
| May 15, 2025 | Stephens & Co. | Mason Carrico | Overweight | Reiterates | $14.00 |
| May 13, 2025 | UBS | Dan Leonard | Neutral | Maintains | $12.00 |
| May 12, 2025 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $15.00 |
| May 12, 2025 | Goldman Sachs | Matthew Sykes | Sell | Maintains | $6.50 |
| May 9, 2025 | JP Morgan | Rachel Vatnsdal | Neutral | Maintains | $9.00 |
| Apr 10, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $12.00 |
| Mar 4, 2025 | Citigroup | Patrick Donnelly | Buy | Maintains | $15.00 |
| Feb 14, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $15.00 |
| Feb 14, 2025 | Morgan Stanley | Tejas Savant | Overweight | Maintains | $26.00 |
| Feb 13, 2025 | Leerink Partners | Mike Kratky | Market Perform | Downgrade | $12.00 |
| Feb 13, 2025 | UBS | Dan Leonard | Neutral | Maintains | $14.00 |
| Feb 13, 2025 | Citigroup | Patrick Donnelly | Buy | Maintains | $20.00 |
| Feb 13, 2025 | JP Morgan | Rachel Vatnsdal | Neutral | Maintains | $12.00 |
| Feb 13, 2025 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $18.00 |
| Feb 13, 2025 | Stifel | Daniel Arias | Buy | Maintains | $18.00 |
| Feb 10, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $18.00 |
| Jan 13, 2025 | Morgan Stanley | Tejas Savant | Overweight | Maintains | $28.00 |
| Nov 1, 2024 | Barclays | Luke Sergott | Overweight | Maintains | $19.00 |
| Oct 30, 2024 | JP Morgan | Rachel Vatnsdal | Neutral | Maintains | $14.00 |
10x Genomics Inc. (TXG) Competitors
The following stocks are similar to 10X Genomics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
TXG
10X Genomics
mkt cap
1.28B
10x Genomics Inc. (TXG) Financial Data
10x Genomics Inc. has a market capitalization of $1.30B with a P/E ratio of -7.2x. The company generates $624.66M in trailing twelve-month revenue with a -25.1% profit margin.
Revenue growth is +9.8% quarter-over-quarter, while maintaining an operating margin of -31.3% and return on equity of -22.0%.
Valuation Metrics
Market Cap
$1.30B
Enterprise Value
$953.46M
P/E Ratio
-7.2x
PEG Ratio
-8.7x
Price/Sales
2.1x
Growth & Margins
Revenue Growth (YoY)
+9.8%
Gross Margin
+68.1%
Operating Margin
-31.3%
Net Margin
-25.1%
EPS Growth
+9.8%
Financial Health
Cash/Price Ratio
+31.9%
Current Ratio
5.4x
Debt/Equity
11.3x
ROE
-22.0%
ROA
-12.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
10x Genomics Inc. (TXG) Business Model
About 10x Genomics Inc.
What They Do
Develops advanced genomic analysis technologies.
Business Model
10x Genomics generates revenue by selling innovative genomic analysis tools and platforms that empower researchers to study complex biological systems. Their products are primarily used in life sciences and healthcare fields, enabling detailed exploration of genetic variations and gene expression.
Additional Information
The company is headquartered in Pleasanton, California, and has a significant impact on scientific research across oncology, immunology, and neuroscience. Its contributions are vital for advancements in personalized medicine and novel therapeutic approaches.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
1,306
CEO
Dr. Serge Saxonov Ph.D.
Country
United States
IPO Year
2019
Website
www.10xgenomics.com10x Genomics Inc. (TXG) Latest News & Analysis
Latest News
Wall Street Analysts Think 10x Genomics (TXG) Could Surge 43.12%: Read This Before Placing a Bet
21 days ago
Quick Summary
Wall Street analysts set an average price target indicating a 43.1% upside for 10x Genomics (TXG), supported by positive earnings estimate revisions.
Why It Matters
Analysts' price targets suggest significant upside for 10x Genomics, indicating potential growth. Positive earnings revisions may further boost investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Why 10x Genomics Stock Was Sliding This Week
27 days ago
Quick Summary
10x Genomics (TXG) shares fell over 9% for the week, impacted by a bearish analyst outlook, according to S&P Global Market Intelligence.
Why It Matters
The bearish analyst sentiment and 9% price drop indicate weakened confidence in 10x Genomics, potentially signaling risk for investors and impacting future performance.
Source: The Motley Fool
Market Sentiment:
Negative
Quick Summary
10x Genomics (TXG) has received a Zacks Rank #2 (Buy) upgrade, indicating improved earnings outlook, which may lead to a potential increase in the stock price.
Why It Matters
The Zacks Rank #2 upgrade signals increased confidence in 10x Genomics' earnings, likely boosting investor sentiment and driving the stock price up in the short term.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
10x Genomics has settled all patent litigation with Bruker Corporation, resolving disputes and potentially enhancing its operational stability moving forward.
Why It Matters
The settlement eliminates litigation risks for 10x Genomics, potentially enhancing its market position and investor confidence, while allowing focus on innovation and growth.
Source: PRNewsWire
Market Sentiment:
Neutral
Wall Street Analysts Believe 10x Genomics (TXG) Could Rally 55.85%: Here's is How to Trade
1 month ago
Quick Summary
Wall Street analysts project a 55.9% potential upside for 10x Genomics (TXG), with positive earnings estimate revisions suggesting potential stock growth.
Why It Matters
A 55.9% potential upside in price targets suggests strong growth expectations for 10x Genomics, while positive earnings revisions may boost investor confidence and drive stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
10x Genomics, Inc. (NASDAQ:TXG) will hold its Q1 2025 earnings conference call on May 8, 2025, at 4:30 PM ET, featuring key company executives and analysts from major firms.
Why It Matters
10x Genomics' earnings call indicates upcoming financial performance insights, key for evaluating growth potential and investment decisions in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About TXG Stock
What is 10x Genomics Inc.'s (TXG) stock forecast for 2025?
Based on our analysis of 19 Wall Street analysts, 10x Genomics Inc. (TXG) has a median price target of $12.00. The highest price target is $18.00 and the lowest is $9.00.
Is TXG stock a good investment in 2025?
According to current analyst ratings, TXG has 7 Buy ratings, 9 Hold ratings, and 0 Sell ratings. The stock is currently trading at $10.87. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TXG stock?
Wall Street analysts predict TXG stock could reach $12.00 in the next 12 months. This represents a 10.4% increase from the current price of $10.87. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is 10x Genomics Inc.'s business model?
10x Genomics generates revenue by selling innovative genomic analysis tools and platforms that empower researchers to study complex biological systems. Their products are primarily used in life sciences and healthcare fields, enabling detailed exploration of genetic variations and gene expression.
What is the highest forecasted price for TXG 10x Genomics Inc.?
The highest price target for TXG is $18.00 from Tejas Savant at Morgan Stanley, which represents a 65.6% increase from the current price of $10.87.
What is the lowest forecasted price for TXG 10x Genomics Inc.?
The lowest price target for TXG is $9.00 from Rachel Vatnsdal at JP Morgan, which represents a -17.2% decrease from the current price of $10.87.
What is the overall TXG consensus from analysts for 10x Genomics Inc.?
The overall analyst consensus for TXG is neutral. Out of 19 Wall Street analysts, 7 rate it as Buy, 9 as Hold, and 0 as Sell, with a median price target of $12.00.
How accurate are TXG stock price projections?
Stock price projections, including those for 10x Genomics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 1:24 PM UTC